tiprankstipranks
Trending News
More News >
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
US Market
Advertisement

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

Compare
2,241 Followers
See the Price Targets and Ratings of:

BMRN Analyst Ratings

Strong Buy
23Ratings
Strong Buy
19 Buy
4 Hold
0 Sell
Based on 23 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$100.38
▲(72.27% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $100.38 with a high forecast of $122.00 and a low forecast of $70.00. The average price target represents a 72.27% change from the last price of $58.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"55":"$55","72":"$72","89":"$89","106":"$106","123":"$123"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$122.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$100.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[55,72,89,106,123],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.14,63.05230769230769,67.96461538461539,72.87692307692308,77.78923076923077,82.70153846153846,87.61384615384615,92.52615384615385,97.43846153846154,102.35076923076923,107.26307692307692,112.17538461538462,117.08769230769231,{"y":122,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.14,61.38923076923077,64.63846153846154,67.8876923076923,71.13692307692307,74.38615384615385,77.63538461538461,80.88461538461539,84.13384615384615,87.38307692307691,90.63230769230769,93.88153846153845,97.13076923076923,{"y":100.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.14,59.05230769230769,59.964615384615385,60.87692307692308,61.78923076923077,62.70153846153846,63.613846153846154,64.52615384615385,65.43846153846154,66.35076923076923,67.26307692307692,68.17538461538462,69.08769230769231,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.21,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$122.00Average Price Target$100.38Lowest Price Target$70.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on BMRN
Oppenheimer
Oppenheimer
$98
Buy
68.18%
Upside
Reiterated
08/26/25
Oppenheimer Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $98.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).
Bernstein
$94$95
Buy
63.03%
Upside
Reiterated
08/19/25
Bernstein Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)Bernstein SocGen Group analyst William Pickering raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $95.00 (from $94.00) while maintaining an Outperform rating.
Barclays Analyst forecast on BMRN
Barclays
Barclays
$86
Buy
47.59%
Upside
Reiterated
08/13/25
BioMarin Pharmaceutical (BMRN) Receives a Buy from Barclays
Evercore ISI Analyst forecast on BMRN
Evercore ISI
Evercore ISI
$110
Buy
88.78%
Upside
Reiterated
08/11/25
Evercore ISI Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Bank of America Securities Analyst forecast on BMRN
Bank of America Securities
Bank of America Securities
$103
Buy
76.76%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Globus Medical (NYSE: GMED) and BioMarin Pharmaceutical (NASDAQ: BMRN)We maintain Buy and see internal/external de-risking milestones for BMRN’s skeletal dysplasia business as largely upside to the stock.
Truist Financial Analyst forecast on BMRN
Truist Financial
Truist Financial
Buy
Reiterated
08/06/25
Truist Financial Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
Guggenheim
$101$106
Buy
81.91%
Upside
Reiterated
08/06/25
BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim
BMO Capital Analyst forecast on BMRN
BMO Capital
BMO Capital
$115
Buy
97.36%
Upside
Reiterated
08/06/25
BioMarin Pharmaceutical (BMRN) Gets a Buy from BMO Capital
Leerink Partners Analyst forecast on BMRN
Leerink Partners
Leerink Partners
$105
Buy
80.20%
Upside
Reiterated
08/05/25
Positive Outlook on BioMarin Pharmaceutical: Strong Financials and Promising Pipeline Drive Buy Rating
J.P. Morgan Analyst forecast on BMRN
J.P. Morgan
J.P. Morgan
$113$116
Buy
99.07%
Upside
Reiterated
08/05/25
Positive Outlook for BioMarin Pharmaceutical Driven by Strong Financial Performance and Growth Opportunities
TD Cowen Analyst forecast on BMRN
TD Cowen
TD Cowen
$120
Buy
105.94%
Upside
Reiterated
08/05/25
BioMarin Pharmaceutical: Strong Financial Performance and Promising Future Drive Buy Rating
Stifel Nicolaus Analyst forecast on BMRN
Stifel Nicolaus
Stifel Nicolaus
$91
Buy
56.17%
Upside
Reiterated
08/05/25
BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus
Morgan Stanley Analyst forecast on BMRN
Morgan Stanley
Morgan Stanley
$96$104
Buy
78.48%
Upside
Reiterated
08/05/25
BioMarin Pharmaceutical: Strong Q2 Performance and Promising Future Drive Buy Rating
William Blair Analyst forecast on BMRN
William Blair
William Blair
Hold
Reiterated
08/05/25
William Blair Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
Cantor Fitzgerald Analyst forecast on BMRN
Cantor Fitzgerald
Cantor Fitzgerald
$90
Buy
54.45%
Upside
Reiterated
08/05/25
Cantor Fitzgerald Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $90.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on BMRN
Oppenheimer
Oppenheimer
$98
Buy
68.18%
Upside
Reiterated
08/26/25
Oppenheimer Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $98.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).
Bernstein
$94$95
Buy
63.03%
Upside
Reiterated
08/19/25
Bernstein Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)Bernstein SocGen Group analyst William Pickering raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $95.00 (from $94.00) while maintaining an Outperform rating.
Barclays Analyst forecast on BMRN
Barclays
Barclays
$86
Buy
47.59%
Upside
Reiterated
08/13/25
BioMarin Pharmaceutical (BMRN) Receives a Buy from Barclays
Evercore ISI Analyst forecast on BMRN
Evercore ISI
Evercore ISI
$110
Buy
88.78%
Upside
Reiterated
08/11/25
Evercore ISI Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Bank of America Securities Analyst forecast on BMRN
Bank of America Securities
Bank of America Securities
$103
Buy
76.76%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Globus Medical (NYSE: GMED) and BioMarin Pharmaceutical (NASDAQ: BMRN)We maintain Buy and see internal/external de-risking milestones for BMRN’s skeletal dysplasia business as largely upside to the stock.
Truist Financial Analyst forecast on BMRN
Truist Financial
Truist Financial
Buy
Reiterated
08/06/25
Truist Financial Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
Guggenheim
$101$106
Buy
81.91%
Upside
Reiterated
08/06/25
BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim
BMO Capital Analyst forecast on BMRN
BMO Capital
BMO Capital
$115
Buy
97.36%
Upside
Reiterated
08/06/25
BioMarin Pharmaceutical (BMRN) Gets a Buy from BMO Capital
Leerink Partners Analyst forecast on BMRN
Leerink Partners
Leerink Partners
$105
Buy
80.20%
Upside
Reiterated
08/05/25
Positive Outlook on BioMarin Pharmaceutical: Strong Financials and Promising Pipeline Drive Buy Rating
J.P. Morgan Analyst forecast on BMRN
J.P. Morgan
J.P. Morgan
$113$116
Buy
99.07%
Upside
Reiterated
08/05/25
Positive Outlook for BioMarin Pharmaceutical Driven by Strong Financial Performance and Growth Opportunities
TD Cowen Analyst forecast on BMRN
TD Cowen
TD Cowen
$120
Buy
105.94%
Upside
Reiterated
08/05/25
BioMarin Pharmaceutical: Strong Financial Performance and Promising Future Drive Buy Rating
Stifel Nicolaus Analyst forecast on BMRN
Stifel Nicolaus
Stifel Nicolaus
$91
Buy
56.17%
Upside
Reiterated
08/05/25
BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus
Morgan Stanley Analyst forecast on BMRN
Morgan Stanley
Morgan Stanley
$96$104
Buy
78.48%
Upside
Reiterated
08/05/25
BioMarin Pharmaceutical: Strong Q2 Performance and Promising Future Drive Buy Rating
William Blair Analyst forecast on BMRN
William Blair
William Blair
Hold
Reiterated
08/05/25
William Blair Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
Cantor Fitzgerald Analyst forecast on BMRN
Cantor Fitzgerald
Cantor Fitzgerald
$90
Buy
54.45%
Upside
Reiterated
08/05/25
Cantor Fitzgerald Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $90.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

1 Month
xxx
Success Rate
15/27 ratings generated profit
56%
Average Return
<+0.01%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of <+0.01% per trade.
3 Months
xxx
Success Rate
11/27 ratings generated profit
41%
Average Return
-2.78%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.74% of your transactions generating a profit, with an average return of -2.78% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
20/45 ratings generated profit
44%
Average Return
-3.31%
reiterated a buy rating 23 days ago
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -3.31% per trade.
2 Years
xxx
Success Rate
10/26 ratings generated profit
38%
Average Return
-7.83%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 38.46% of your transactions generating a profit, with an average return of -7.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
13
18
17
24
26
Buy
14
13
12
16
18
Hold
8
8
8
7
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
39
37
47
49
In the current month, BMRN has received 44 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 100.38.
Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $0.87 with a range of $0.65 to $1.18. The previous quarter’s EPS was $1.23. BMRN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.
Next quarter’s earnings estimate for BMRN is $0.87 with a range of $0.65 to $1.18. The previous quarter’s EPS was $1.23. BMRN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $790.83M with a range of $769.81M to $838.01M. The previous quarter’s sales results were $827.47M. BMRN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.
Next quarter’s sales forecast for BMRN is $790.83M with a range of $769.81M to $838.01M. The previous quarter’s sales results were $827.47M. BMRN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 100.38.
    What is BMRN’s upside potential, based on the analysts’ average price target?
    BioMarin Pharmaceutical has 72.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BMRN a Buy, Sell or Hold?
          BioMarin Pharmaceutical has a consensus rating of Strong Buy which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
            What is BioMarin Pharmaceutical’s price target?
            The average price target for BioMarin Pharmaceutical is 100.38. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $122.00 ,the lowest forecast is $70.00. The average price target represents 72.27% Increase from the current price of $58.27.
              What do analysts say about BioMarin Pharmaceutical?
              BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of BMRN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis